Catalyst
Slingshot members are tracking this event:
OncoSec Medical's (ONCS) Interim Results from Phase 2 Study of ImmunoPulse IL-12 and Merck's (MRK) KEYTRUDA in Unresectable Metastatic Melanoma to be Presented at the Society for Immunotherapy of Cancer Annual Meeting
Do you think this event is important to the companies below? How will it affect their stock price?
Slingshot Insights Explained
Catalyst Date
Occurred on:
Nov 11, 2016
Occurred Source:
http://ir.oncosec.com/press-releases/detail/1886/oncosec-presents-positive-interim-response-data-at-the
Related Projects
-
Don’t see a project related to the catalyst you care about?
Related Keywords
Phase 2, Immunopulse Il-12, Keytruda, Unresectable Metastatic Melanoma, Society For Immunotherapy Of Cancer
